Publication date: December 2026 Source: Diabetes Research and Clinical Practice, Volume 242 Author(s): Omer Abdelgadir, Jesus Gibran Hernández-Pérez, Maryam R. Hussain, Kenny Mendoza, Rabiya K. Mian, Mohanad Albayyaa, Amy Hughes, Jaime P. Almandoz, Lindsay G. Cowell, Sarah E. Messiah, David S. Lopez
Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors. // Diabetes Research and Clinical Practice. – URL: https://www.sciencedirect.com/science/article/pii/S0168822726005383?dgcid=rss_sd_all
Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors. Diabetes Research and Clinical Practice. https://www.sciencedirect.com/science/article/pii/S0168822726005383?dgcid=rss_sd_all
“Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors.” Diabetes Research and Clinical Practice.
@article{article43129,
title = {Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors},
journal = {Diabetes Research and Clinical Practice},
url = {https://www.sciencedirect.com/science/article/pii/S0168822726005383?dgcid=rss_sd_all}
}
Abstract Background Macrophage polarisation plays a crucial role in sepsis‐associated inflammatory responses; however, the underlying molecular regulatory mechanisms remain to be further explored. Aim This study aimed to explore the...